ID   HO-8910
AC   CVCL_6868
SY   Ho-8910; HO8910; Ho8910
DR   BTO; BTO:0005438
DR   Wikidata; Q38151529
RX   PubMed=8082435;
RX   PubMed=11930655;
RX   PubMed=25502083;
RX   PubMed=26116706;
CC   Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706; CCRID). Originally thought to originate from the ascites of a 51 year old female patient with ovarian serous cystadenocarcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00606.
CC   Population: African American.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000280, 3131C0001000700024). They were one of the sources for the STR profile of this entry.
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): CCRID; PubMed=26116706
ST   Amelogenin: X
ST   CSF1PO: 9,10 (PubMed=26116706)
ST   D12S391: 20,25
ST   D13S317: 13.3
ST   D16S539: 9,10
ST   D18S51: 16 (CCRID)
ST   D18S51: 16,17 (PubMed=26116706)
ST   D19S433: 13 (CCRID)
ST   D19S433: 13,14 (PubMed=26116706)
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 11,12 (PubMed=26116706)
ST   D5S818: 12 (CCRID)
ST   D6S1043: 18
ST   D7S820: 8,12 (PubMed=26116706)
ST   D7S820: 12 (CCRID)
ST   D8S1179: 12 (CCRID)
ST   D8S1179: 12,13 (PubMed=26116706)
ST   FGA: 18,21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12 (PubMed=26116706)
ST   vWA: 16,17,18 (CCRID)
ST   vWA: 16,18 (PubMed=26116706)
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
RX   PubMed=8082435;
RA   Mou H.-Z., Xu S.-H., Zhang Y.-Y.;
RT   "The establishment of human ovarian carcinoma cell line HO-8910 and
RT   its characteristics.";
RL   Zhonghua Fu Chan Ke Za Zhi 29:162-164(1994).
RX   PubMed=11930655; DOI=10.3760/cma.j.issn.0366-6999.2002.01.107;
RA   Xu S.-H., Mou H.-Z., Lu G.-Q., Zhu C.-H., Yang Z.-Y., Gao Y.-L.,
RA   Lou H.-K., Liu X.-L., Cheng Y., Yang W.;
RT   "Gene expression profile differences in high and low metastatic human
RT   ovarian cancer cell lines by gene chip.";
RL   Chin. Med. J. 115:36-41(2002).
RX   PubMed=25502083; DOI=10.1007/s12032-014-0426-5;
RA   Zhu L.-C., Hu Z.-H., Liu J.-J., Gao J., Lin B.;
RT   "Gene expression profile analysis identifies metastasis and
RT   chemoresistance-associated genes in epithelial ovarian carcinoma
RT   cells.";
RL   Med. Oncol. 32:426.1-426.13(2015).
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).